GenMark Diagnostics Director Kevin C. Oboyle Unloads 1,603 Shares (GNMK)
GenMark Diagnostics (NASDAQ:GNMK) Director Kevin C. Oboyle sold 1,603 shares of the company’s stock in a transaction that occurred on Thursday, May 29th. The stock was sold at an average price of $10.98, for a total value of $17,600.94. Following the sale, the director now directly owns 30,174 shares in the company, valued at approximately $331,311. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link.
Several analysts have recently commented on the stock. Analysts at Raymond James reiterated an “outperform” rating on shares of GenMark Diagnostics in a research note on Wednesday, May 7th. They now have a $11.00 price target on the stock, down previously from $14.00. Separately, analysts at JPMorgan Chase & Co. reiterated an “overweight” rating on shares of GenMark Diagnostics in a research note on Wednesday, May 7th. They now have a $16.00 price target on the stock, down previously from $17.00. Finally, analysts at Cowen and Company reiterated an “outperform” rating on shares of GenMark Diagnostics in a research note on Wednesday, May 7th. They now have a $15.00 price target on the stock, down previously from $16.00. Five analysts have rated the stock with a buy rating, The stock presently has an average rating of “Buy” and a consensus price target of $15.00.
Shares of GenMark Diagnostics (NASDAQ:GNMK) traded down 1.96% on Friday, hitting $11.01. 370,303 shares of the company’s stock traded hands. GenMark Diagnostics has a 1-year low of $8.48 and a 1-year high of $15.49. The stock has a 50-day moving average of $9.38 and a 200-day moving average of $11.44. The company’s market cap is $458.1 million.
GenMark Diagnostics (NASDAQ:GNMK) last posted its quarterly earnings results on Tuesday, May 6th. The company reported ($0.21) earnings per share for the quarter, beating the analysts’ consensus estimate of ($0.25) by $0.04. The company had revenue of $7.91 million for the quarter, compared to the consensus estimate of $6.40 million. During the same quarter last year, the company posted ($0.13) earnings per share. GenMark Diagnostics’s revenue was down 28.7% compared to the same quarter last year. Analysts expect that GenMark Diagnostics will post $-1.15 EPS for the current fiscal year.
GenMark Diagnostics, Inc (NASDAQ:GNMK) is a molecular diagnostics company focused on developing and commercializing its eSensor detection technology.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.